| Guidance |
Costing tool |
| Technology appraisal - methadone and buprenorphine for the management of opioid dependence |
Estimated cost impact of implementing this guidance is £6.9 million. Costing tool is available. |
| Technology appraisal - naltrexone for the management of opioid dependence (TA115) |
The recommendations made were not considered to have significant cost impact. Costing statement produced.
|
| Public health intervention: interventions to reduce substance misuse among vulnerable young people (PHI4) |
Costing work carried out in conjunction with the clinical guideline costings. Estimated cost impact of implementing this guidance is £8.1 million.
|
| Clinical guideline - drug misuse – psychosocial interventions (CG51) |
Costing work carried out on both pieces of guidance with input from the National Treatment Agency. The estimated cost impact is £13.4 million.
|
Clinical guideline – drug misuse – opioid detoxification (CG52)
|
Costing work carried out on both pieces of guidance with input from the National Treatment Agency. The estimated cost impact is £13.4 million.
|
